{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041285","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.916959+00:00","generated_at":"2026-06-11T18:19:15.167878+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Frequency Therapeutics Q2 net loss narrows to $10.8M; merger with Korro Bio expected Q4 2023","bullets":["Net loss of $10.8M for Q2 2023, down from $21.3M in Q2 2022 due to hearing program discontinuation.","Cash, equivalents and marketable securities $46.5M; all outstanding debt prepaid in April.","Definitive merger agreement with Korro Bio, expected close Q4 2023; combined company to trade as 'KRRO'.","Stockholders may receive CVR for remyelination program if not monetized before merger close.","R&D expenses fell to $4.6M from $13.3M; G&A expenses $7.2M vs $8.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041285","json":"https://secwatch.observer/filing/0000950170-23-041285.json","markdown":"https://secwatch.observer/filing/0000950170-23-041285.md","text":"https://secwatch.observer/filing/0000950170-23-041285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000095017023041285/0000950170-23-041285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000095017023041285/freq-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:19:15.167878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c894cbbb7afae783f9b0bd7f9ca476f6d840d9e8","claim":"Korro Bio, Inc. reported the six months ended June 30, 2023 results: net income $30.3 million.","evidence_excerpt":"Net loss was $30.3 million for the six months ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017023041285/0000950170-23-041285-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Net income","value":"$30.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ea557419fa5e9beb4155d1ea7b7be9a2de294797","claim":"Korro Bio, Inc. reported the three months ended June 30, 2023 results: net income $10.8 million.","evidence_excerpt":"Net loss was $10.8 million for the three months ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017023041285/0000950170-23-041285-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended June 30, 2023"},{"label":"Net income","value":"$10.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}